Please find enclosed herewith announcement relating to Product Launch.
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Royal Sense Limited announced the launch of 9 new pharmaceutical products in the domestic Indian market on 19th May 2025. The new products include antibiotics (CPUDM CV, STEROCIP), corticosteroids (DFACORT 6mg tablets and syrup), a pain and antispasmodic combination (DROTRIN MF), a lactulose laxative (2PHALAC), a sildenafil-dapoxetine tablet (I-DELAY), a cyproheptadine-sorbitol syrup (CY POWER), and a diclofenac topical gel (IONFLAM GEL). All products fall under the Pharmaceuticals category and will be sold only in the domestic market, not internationally. The company is relatively new, incorporated in 2023, and this launch marks a notable expansion of its product portfolio across multiple therapeutic segments. The disclosure was made under SEBI Regulation 30, but no revenue guidance, order details, or financial projections were provided alongside the launch.
The product expansion broadens the company's pharmaceutical portfolio across multiple therapy areas, which could support future revenue growth, but the announcement provides no financial forecasts or expected sales contribution, so investors should wait for further updates to gauge commercial impact.